Stay updated on Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page
- Check3 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check10 days agoChange Detected- The revision tag on the page updated from v3.4.2 to v3.4.3. No visible content changes are indicated.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedAdministrative site updates: the page now lists Revision: v3.4.2 and the older funding-status notice and Revision: v3.4.1 have been removed; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check46 days agoChange DetectedThe page now includes a government funding notice about NIH operations and the revision tag was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check53 days agoChange DetectedThe changes are cosmetic and metadata-related, including Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, which do not alter core study content, eligibility criteria, outcomes, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page history shows a minor revision update: 'Revision: v3.3.4' was added and 'Revision: v3.3.3' was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page.